| Market Capitalization (Millions $) |
0 |
| Shares
Outstanding (Millions) |
5 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-21 |
| Cash Flow (TTM) (Millions $) |
-34 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Calithera Biosciences Inc is a clinical-stage biotechnology company that focuses on developing innovative therapies to target tumor metabolism and the tumor microenvironment. The company's research and development efforts are centered around understanding metabolic pathways and using that knowledge to develop small molecule drugs.
Calithera's flagship drug candidate is CB-839, an orally available glutaminase inhibitor. Glutaminase is an enzyme that plays a critical role in tumor growth and survival by providing energy and building blocks for cancer cells. By inhibiting glutaminase, CB-839 aims to disrupt tumor metabolism and potentially halt tumor growth.
The company is also developing other drug candidates that target various metabolic pathways and exploit vulnerabilities in the tumor microenvironment. These candidates include INCB01158, an oral arginase inhibitor, and INCB81822, an oral inhibitor of the enzyme CD73, which is involved in suppressing the immune response to cancer.
Calithera Biosciences collaborates with leading academic institutions, pharmaceutical companies, and research organizations to advance its drug development programs. The company's goal is to develop novel therapies that have the potential to provide meaningful clinical benefit to patients with cancer.
Company Address: 343 Oyster Point Blvd. South San Francisco 94080 CA
Company Phone Number: 870-1000 Stock Exchange / Ticker: NASDAQ CALA
|
0.000%
10.05%